Sedana Medical announces the recruitment of Peter Sackey, MD, PhD as Chief Medical Officer (CMO).
Sackey has over twenty years’ clinical experience as an anesthesiologist and ICU physician and has been recruited from a position as Senior Consultant and Associate Professor at the Department of Intensive Care Medicine, Perioperative Medicine and Intensive Care, Karolinska University Hospital in Sweden. Peter Sackey is one of the leading researchers in inhalation sedation in the world and was the first to use AnaConDa in intensive care.
Peter Sackey has a strong clinical and scientific background in the field of Intensive Care Medicine and clinical research. After completing his thesis “Isoflurane sedation in ICU patients” he has supervised PhD students in the field of ICU sedation and analgesia as well as ICU follow-up. Peter, who is certified in Intensive Care Medicine (EDIC) has led several clinical trials and multicenter studies and has also been involved in medical product development and has had a central role in Research and Development in Anesthsiology and Intensive Care Medicine for many years.
Peter will start as CMO on 8th January 2018 and will initially focus on Sedana Medical’s primary pharmaceutical drug candidate IsoConDa. The product is in an advanced phase in its clinical development, targeting its use for sedation of critically ill ICU patients. The recruitment of Peter Sackey will accelerate the activities in building an effective organization to support the overall company strategy for the registration and marketing of IsoconDa together with AnaConDa in Europe and the US.
“We are very happy to strengthen our organization with Peter Sackey in this exciting phase of development for Sedana Medical. His extensive clinical and scientific background together with his experience in building and developing strong teams will be a cornerstone in the marketing of IsoConDa together with AnaConda for Intensive Care” says Christer Ahlberg, CEO of Sedana Medical.